Jom 13

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H596274

CAS#: 117550-12-6

Description: Jom 13 is a cyclic delta receptor selective tetrapeptide.

Chemical Structure

img
Jom 13
CAS# 117550-12-6
Instruction

Theoretical Analysis

Hodoodo Cat#: H596274
Name: Jom 13
CAS#: 117550-12-6
Chemical Formula: C26H34N4O6S2
Exact Mass: 562.19
Molecular Weight: 562.700
Elemental Analysis: C, 55.50; H, 6.09; N, 9.96; O, 17.06; S, 11.40

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Jom 13; H-Tyrosyl-cyclo(cysteinyl-phenylalanyl-penicillaminyl)-OH; DCFPE; Htdcpdp-OH;

IUPAC/Chemical Name: (S)-2-((S)-2-((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-3-mercaptopropanamido)-3-phenylpropanoic (S)-2-amino-3-mercapto-3-methylbutanoic anhydride

InChi Key: LINHQEFGHROEAQ-BURNTYAHSA-N

InChi Code: InChI=1S/C26H34N4O6S2/c1-26(2,38)21(28)25(35)36-24(34)19(13-15-6-4-3-5-7-15)29-23(33)20(14-37)30-22(32)18(27)12-16-8-10-17(31)11-9-16/h3-11,18-21,31,37-38H,12-14,27-28H2,1-2H3,(H,29,33)(H,30,32)/t18-,19-,20+,21-/m0/s1

SMILES Code: CC([C@@H](N)C(OC([C@@H](NC([C@H](NC([C@@H](N)Cc1ccc(O)cc1)=O)CS)=O)Cc2ccccc2)=O)=O)(S)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 562.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 2006 Jan 19;1069(1):172-81. Epub 2005 Dec 20. PubMed PMID: 16364263; PubMed Central PMCID: PMC1780167.

2: Mosberg HI, Fowler CB. Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity. J Pept Res. 2002 Dec;60(6):329-35. PubMed PMID: 12464111.

3: Mosberg HI. Complementarity of delta opioid ligand pharmacophore and receptor models. Biopolymers. 1999;51(6):426-39. Review. PubMed PMID: 10797231.

4: Mansour A, Taylor LP, Fine JL, Thompson RC, Hoversten MT, Mosberg HI, Watson SJ, Akil H. Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J Neurochem. 1997 Jan;68(1):344-53. PubMed PMID: 8978745.

5: Mosberg HI, Dua RK, Pogozheva ID, Lomize AL. Development of a model for the delta-opioid receptor pharmacophore. 4. Residue 3 dehydrophenylalanine analogues of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic side chain. Biopolymers. 1996 Sep;39(3):287-96. PubMed PMID: 8756510.

6: Gao P. Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study. J Comput Aided Mol Des. 1996 Aug;10(4):327-36. PubMed PMID: 8877704.

7: Brandt W, Stoldt M, Schinke H. The mu- and delta-opioid pharmacophore conformations of cyclic beta-casomorphin analogues indicate docking of the Phe3 residue to different domains of the opioid receptors. J Comput Aided Mol Des. 1996 Jun;10(3):201-12. PubMed PMID: 8808737.

8: Lomize AL, Pogozheva ID, Mosberg HI. Development of a model for the delta-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]OH with other conformationally constrained delta-receptor selective ligands. Biopolymers. 1996 Feb;38(2):221-34. PubMed PMID: 8589255.

9: Deschamps JR, George C, Flippen-Anderson JL. Structural studies of opioid peptides: a review of recent progress in x-ray diffraction studies. Biopolymers. 1996;40(1):121-39. Review. PubMed PMID: 8541444.

10: Mosberg HI, Omnaas JR, Lomize A, Heyl DL, Nordan I, Mousigian C, Davis P, Porreca F. Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J Med Chem. 1994 Dec 9;37(25):4384-91. PubMed PMID: 7996550.

11: Mosberg HI, Lomize AL, Wang C, Kroona H, Heyl DL, Sobczyk-Kojiro K, Ma W, Mousigian C, Porreca F. Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J Med Chem. 1994 Dec 9;37(25):4371-83. PubMed PMID: 7996549.

12: Heyl DL, Schmitter SJ, Bouzit H, Johnson TW, Hepp AM, Kurtz KR, Mousigian C. Substitution of aromatic and nonaromatic amino acids for the Phe3 residue in the delta-selective opioid peptide deltorphin I: effects on binding affinity and selectivity. Int J Pept Protein Res. 1994 Nov;44(5):420-6. PubMed PMID: 7896499.

13: Mosberg HI, Kroona HB. Incorporation of a novel conformationally restricted tyrosine analog into a cyclic, delta opioid receptor selective tetrapeptide (JOM-13) enhances delta receptor binding affinity and selectivity. J Med Chem. 1992 Nov 13;35(23):4498-500. PubMed PMID: 1333014.

14: Heyl DL, Mosberg HI. Modification of the Phe3 aromatic moiety in delta receptor-selective dermorphin/deltorphin-related tetrapeptides. Effects on opioid receptor binding. Int J Pept Protein Res. 1992 May;39(5):450-7. PubMed PMID: 1330964.

15: Nikiforovich GV, Hruby VJ, Prakash O, Gehrig CA. Topographical requirements for delta-selective opioid peptides. Biopolymers. 1991 Jul;31(8):941-55. PubMed PMID: 1782355.

16: Heyl DL, Omnaas JR, Sobczyk-Kojiro K, Medzihradsky F, Smith CB, Mosberg HI. Opioid receptor affinity and selectivity effects of second residue and carboxy terminal residue variation in a cyclic disulfide-containing opioid tetrapeptide. Int J Pept Protein Res. 1991 Mar;37(3):224-9. PubMed PMID: 1651290.